Staff View
Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder

Descriptive

TypeOfResource
Text
TitleInfo
Title
Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder
Name (type = personal)
NamePart (type = family)
Liu
NamePart (type = given)
Mei T.
Affiliation
Pharmacy Practice and Administration, Rutgers University
Role
RoleTerm (authority = marcrt); (type = text)
author
Name (authority = orcid); (authorityURI = http://id.loc.gov/vocabulary/identifiers/orcid.html); (type = personal); (valueURI = http://orcid.org/0000-0002-2718-6787)
NamePart (type = family)
Maroney
NamePart (type = given)
Megan E.
Affiliation
Pharmacy Practice and Administration, Rutgers University
Role
RoleTerm (authority = marcrt); (type = text)
author
Name (type = personal)
NamePart (type = family)
Hermes-DeSantis
NamePart (type = given)
Evelyn R.
Affiliation
Pharmacy Practice and Administration, Rutgers University
Role
RoleTerm (authority = marcrt); (type = text)
author
Name (authority = RutgersOrg-Department); (type = corporate)
NamePart
Pharmacy Practice and Administration
Name (authority = RutgersOrg-School); (type = corporate)
NamePart
Ernest Mario School of Pharmacy
Genre (authority = RULIB-FS)
Article, Refereed
Genre (authority = NISO JAV)
Version of Record (VoR)
OriginInfo
DateIssued (encoding = w3cdtf); (keyDate = yes); (qualifier = exact)
2015
Language
LanguageTerm (authority = ISO 639-3:2007); (type = text)
English
PhysicalDescription
InternetMediaType
application/pdf
Extent
15 p.
Extension
DescriptiveEvent
Type
Citation
DateTime (encoding = w3cdtf)
2015
AssociatedObject
Name
World Journal of Pharmacology
Type
Journal
Relationship
Has part
Detail
17-30
Identifier (type = volume and issue)
4(1)
Reference (type = url)
https://dx.doi.org/doi:10.5497/wjp.v4.i1.17
Subject (authority = LCSH)
Topic
Depression, Mental--Treatment
Subject (authority = LCSH)
Topic
Antidepressants
Subject (authority = local)
Topic
Levomilnacipran
Subject (authority = local)
Topic
Vortioxetine
Abstract (type = abstract)
Major depressive disorder (MDD) is a common psychiatric disorder with an estimated lifetime prevalence rate in the range of 13% to 16% in the United States population. Patients with MDD often have symptoms such as depressed mood, loss of interest or pleasure in usual activities, changes in eating or sleeping patterns, fatigue, difficulty concentrating and thoughts of suicide. Although many pharmacotherapy treatment options are available for MDD, antidepressants can often cause adverse effects that could affect adherence to the medication. Additionally, it is estimated that MDD is unremitting in 15% of patients and 35% can have recurrent episodes. Given the high rate of recurrence and the adverse effects associated with existing medications, new treatment options for depression are needed. Both levomilnacipran and vortioxetine are new antidepressants that were approved by the food and drug administration in 2013 for the treatment of MDD in adults. Levomilnacipran is a serotonin norepinephrine reuptake inhibitor that was effective in several short term studies and sustained efficacy and tolerability was demonstrated in a 48-wk extension study. Vortioxetine is a multi-modal antidepressant and it is thought to work via inhibition of the serotonin (5-HT) transporter, 5-HT3A, 5-HT7 and 5-HT1D antagonist, a 5-HT1B partial agonist, and a 5-HT1A agonist. Vortioxetine was effective in the treatment of MDD in both short-term trials as well as in the prevention of relapse in a 24-36 wk trial. Sustained efficacy and tolerability was demonstrated in several long-term open-label trials. Further studies comparing levomilnacipran and vortioxetine to other currently available antidepressants are needed to establish its place in therapy.
RelatedItem (type = host)
TitleInfo
Title
Maroney, Megan E.
Identifier (type = local)
rucore30203800001
RelatedItem (type = host)
TitleInfo
Title
Hermes-Desantis, Evelyn R.
Identifier (type = local)
rucore30176100001
Location
PhysicalLocation (authority = marcorg); (displayLabel = Rutgers, The State University of New Jersey)
NjNbRU
Identifier (type = doi)
doi:10.7282/T3VM4FCW
Genre (authority = ExL-Esploro)
Journal Article
Back to the top

Rights

RightsDeclaration (AUTHORITY = FS); (ID = rulibRdec0004)
Copyright for scholarly resources published in RUcore is retained by the copyright holder. By virtue of its appearance in this open access medium, you are free to use this resource, with proper attribution, in educational and other non-commercial settings. Other uses, such as reproduction or republication, may require the permission of the copyright holder.
Copyright
Status
Copyright protected
Availability
Status
Open
Reason
Permission or license
RightsEvent
Type
Permission or license
AssociatedObject
Type
License
Name
Multiple author license v. 1
Detail
I hereby grant to Rutgers, The State University of New Jersey (Rutgers) the non-exclusive right to retain, reproduce, and distribute the deposited work (Work) in whole or in part, in and from its electronic format, without fee. This agreement does not represent a transfer of copyright to Rutgers.Rutgers may make and keep more than one copy of the Work for purposes of security, backup, preservation, and access and may migrate the Work to any medium or format for the purpose of preservation and access in the future. Rutgers will not make any alteration, other than as allowed by this agreement, to the Work.I represent and warrant to Rutgers that the Work is my original work. I also represent that the Work does not, to the best of my knowledge, infringe or violate any rights of others.I further represent and warrant that I have obtained all necessary rights to permit Rutgers to reproduce and distribute the Work and that any third-party owned content is clearly identified and acknowledged within the Work.By granting this license, I acknowledge that I have read and agreed to the terms of this agreement and all related RUcore and Rutgers policies.
RightsEvent
Type
Publication notice
Detail
Baishideng Publishing Group Inc applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Back to the top

Technical

RULTechMD (ID = TECHNICAL1)
ContentModel
Document
Back to the top
Version 8.3.13
Rutgers University Libraries - Copyright ©2020